benzyl 2,2-dimethylpent-4-enoate | 143688-43-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 2,2-dimethylpent-4-enoate
• CAS: 143688-43-1
• 化学式: C₁₄H₁₈O₂
• 分子量: 218.296
• InChiKey: LWTUYGFPPYWWPV-UHFFFAOYSA-N

物化性质

• 沸点：
  272.6±9.0 °C(Predicted)
• 密度：
  0.992±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  benzyl 2,2-dimethylpent-4-enoate 在 sodium hydroxide 、 9-borabicyclononane 、 双氧水 作用下， 生成 苯甲醇
  参考文献：
  名称：

  Pinacol-type rearrangements of intramolecular photocycloadducts: Application of the 2,2-dimethyl-4-pentenoate protecting group

  摘要：

  A pinacol-type rearrangement of intramolecular photocycloadducts has been accomplished by exploiting a novel ester protecting group that can be easily removed from a hindered alcohol. The ester is removed by an intramolecular lactonization, overcoming the steric factors normally associated with pivalate esters. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)01465-8
• 作为产物：
  描述：

  2,2-二甲基-4-戊酸甲酯 在 sodium hydroxide 、 氯化亚砜 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 、 苯 为溶剂， 反应 30.0h， 生成 benzyl 2,2-dimethylpent-4-enoate
  参考文献：
  名称：

  Pinacol-type rearrangements of intramolecular photocycloadducts: Application of the 2,2-dimethyl-4-pentenoate protecting group

  摘要：

  A pinacol-type rearrangement of intramolecular photocycloadducts has been accomplished by exploiting a novel ester protecting group that can be easily removed from a hindered alcohol. The ester is removed by an intramolecular lactonization, overcoming the steric factors normally associated with pivalate esters. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)01465-8

文献信息

• Substituted monocyclic CGRP receptor antagonists
  申请人：Wood Michael R.

  公开号：US20070265225A1

  公开（公告）日：2007-11-15

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , m, n, J, Q, R 4 , E a , E b , E c , R 6 , R 7 , R e , R f , R PG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  式I的化合物：(其中变量A1、A2、A3、A4、m、n、J、Q、R4、Ea、Eb、Ec、R6、R7、Re、Rf、RPG和Y如本文所述)是CGRP受体拮抗剂，可用于治疗或预防涉及CGRP的疾病，如偏头痛。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及CGRP的疾病中使用这些化合物和组合物。
• Oxidation of Hindered Allylic C–H Bonds with Applications to the Functionalization of Complex Molecules
  作者：Zachary C. Litman、Ankit Sharma、John F. Hartwig

  DOI：10.1021/acscatal.6b03648

  日期：2017.3.3

  oxidation of hindered alkenes to form linear allylic esters. The combination of palladium(II) benzoate, 4,5-diazafluoren-9-one, and benzoquinone catalyzes the mild oxidation of terminal alkenes with tert-butyl benzoyl peroxide as an oxidant in the presence of diverse functional groups. Selective oxidation of terminal alkenes in the presence of trisubstituted and disubstituted alkenes has been achieved

  我们报道了钯催化的受阻烯烃氧化形成线性烯丙基酯。苯甲酸钯（II），4,5-二氮杂芴-9-一和苯醌的组合在多种官能团存在的情况下用叔丁基苯甲酰过氧化物作为氧化剂催化末端烯烃的轻度氧化。已经实现了在三取代和二取代的烯烃的存在下末端烯烃的选择性氧化，并且已经证明了以克规模进行反应的能力。温和的条件和对辅助功能的高度耐受性使该方法适用于复杂分子的合成和衍生化。
• SUBSTITUTED MONOCYCLIC CGRP RECEPTOR ANTAGONISTS
  申请人：Wood Michael R.

  公开号：US20100056498A1

  公开（公告）日：2010-03-04

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , m, n, J, Q, R 4 , E a , E b , E c , R 6 , R 7 , R e , R f , R PG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  式I的化合物：（其中变量A1，A2，A3，A4，m，n，J，Q，R4，Ea，Eb，Ec，R6，R7，Re，Rf，RPG和Y如本文所述）是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗CGRP参与的这些疾病中的应用。
• [EN] DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES<br/>[FR] DÉRIVÉS DE DIHYDROPYRIMIDINE ET LEURS UTILISATIONS DANS LE TRAITEMENT D'UNE INFECTION PAR LE VHB OU DE MALADIES INDUITES PAR LE VHB
  申请人：JANSSEN SCIENCES IRELAND UNLIMITED CO

  公开号：WO2022161448A1

  公开（公告）日：2022-08-04

  The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

  该申请描述了二氢嘧啶衍生物，其在治疗或预防HBV感染或由HBV感染引起的疾病，特别是HBV慢性感染或由HBV慢性感染引起的疾病方面具有用途，以及其药物或医学应用。
• SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2024358B1

  公开（公告）日：2014-11-05